Excisional Vacuum-Assisted Breast Biopsy

Sponsor
European Institute of Oncology (Other)
Overall Status
Recruiting
CT.gov ID
NCT05932758
Collaborator
Ministero della Salute, Italy (Other)
300
1
2
30.4
9.9

Study Details

Study Description

Brief Summary

The goal of this prospective cohort study is to evaluate the possibility of vacuum-assisted excisional biopsy (VAE) to completely remove the pathology in case of small lesions for Atypical Ductal Hyperplasia (ADH) and low-intermediate grade Ductal Carcinoma in Situ (DCIS).

Condition or Disease Intervention/Treatment Phase
  • Procedure: Vacuum-assisted excisional biopsy
N/A

Detailed Description

Surgery is the current standard of care of breast lesions like the Ductal Carcinoma In Situ (DCIS) and the Atypical Ductal Hyperplasia (ADH). However, the survival benefit of surgical resection in patients with such lesions appears to be low, especially for ADH and low-grade DCIS where comorbidity of surgery and prior depression have been reported as important factors related to worse quality of life in these women.

Patients with suspicious breast lesions (BIRADS>3) who are candidates for vacuum assisted breast biopsy will be prospectively select and enroll if the radiological lesion diameter is less than 15 mm.

We will select those patients in whom after an initial sequence of sampling (12 cores) we will check the complete macroscopic removal of the lesion (with radiograms of the biopsied part of the breast). Those patients (complete macroscopic removal, with real-time verification during the procedure) will be randomized into two groups. A first group of patients will finish the biopsy procedure after the first collection sequence (12 cores, 3 grams of tissue taken and complete macroscopic removal). A second group of patients (randomized subdivision) will undergo a second sequence of biopsy samples (other 4 cores and 1 gram of tissue taken) in the same session: the material collected will be sent separately to the pathologist.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Excisional Vacuum-Assisted Breast Biopsy (VAE): Application to Avoid Surgery in Atypical Ductal Hyperplasia and Low/Intermediate Grade Ductal Carcinoma in Situ of the Breast
Actual Study Start Date :
Jan 17, 2023
Anticipated Primary Completion Date :
Apr 30, 2025
Anticipated Study Completion Date :
Jul 31, 2025

Arms and Interventions

Arm Intervention/Treatment
No Intervention: no excisional biopsy

Patients in this arm underwent to an initial sequence of sampling (less than 4 g of tissue sampled)

Experimental: excisional biosy

Patients in this arm will undergo a second sequence of biopsy samples (at least 4g sampled)

Procedure: Vacuum-assisted excisional biopsy
at least 4g of tissue sampled (excisional biopsy)

Outcome Measures

Primary Outcome Measures

  1. Percentage of patients with complete removal of lesion [6 months]

    Comparison of the percentage of patients with a lack of pathology (also in situ) at the surgery between the two groups

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with suspicious breast lesions (BIRADS >3)

  • Patients with a lesion <= of 15mm.

  • Capable and willing to comply the specific informed consent form

  • Patients with ADH biopsy results or low intermediate-grade DCIS

  • Patients who will undergo surgery

Exclusion Criteria:
  • Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS Milan Italy 20141

Sponsors and Collaborators

  • European Institute of Oncology
  • Ministero della Salute, Italy

Investigators

  • Principal Investigator: Luca Nicosia, MD, European Institute of Oncology IRCCS

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
European Institute of Oncology
ClinicalTrials.gov Identifier:
NCT05932758
Other Study ID Numbers:
  • IEO 1856
First Posted:
Jul 6, 2023
Last Update Posted:
Jul 6, 2023
Last Verified:
Jun 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 6, 2023